Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 656 (miR-656) is a member of the large miR-379/656 cluster, also known as C14MC, located in the imprinted DLK1-Dio3 region at human chromosome 14q32.3. MiR-656 is a small non-coding RNA molecule that post-transcriptionally regulates gene expression by binding to complementary sequences in the 3’ UTR regions of target mRNAs, leading to their repression. The miR-379/656 cluster, including miR-656, is implicated in diverse biological and pathological processes, including development, vascular remodeling, and especially cancer. In multiple tumor types such as breast and colorectal cancer, miR-656 expression is frequently downregulated. In colorectal cancer, miR-656-3p inhibits proliferation, migration, invasion, and chemoresistance of cancer cells, partly by targeting sphingosine-1-phosphate phosphatase 1 (SGPP1). In breast cancer, altered expression of miRNAs in the miR-379/656 cluster serves as a strong diagnostic and prognostic marker, particularly for Basal and Luminal B subtypes[1][2][3].
Binds to 3’ untranslated region (UTR) of target mRNA (SGPP1), inhibiting translation or leading to mRNA degradation[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 656 (miR-656).